Amneal rises after US FDA nod for generic asthma inhaler

Amneal Pharmaceuticals

02/12/2025 13:35

** Shares of drugmaker Amneal Pharmaceuticals AMRX.O rise 1.2% to $12.45 premarket

** Co says U.S. FDA approved its generic version of a widely used asthma drug, albuterol sulfate inhalation aerosol

** Approval comes after FDA cleared co's generic version of Teva's TEVA.TA QVAR inhaler for asthma - AMRX

** Co says both approvals mark progress in complex respiratory drug market

** Up to last close, stock up ~55% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))